Cargando…

Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States

BACKGROUND: Recurrence of early‐stage non‐small cell lung cancer (eNSCLC) is associated with significant mortality and costs. Atezolizumab (ATZ) was recently approved as adjuvant treatment following resection and platinum‐based chemotherapy for adults with stage II‐IIIA NSCLC with PD‐L1 expression ≥...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Rishika, Ogale, Sarika, Smith, Nathaniel J., Lee, Janet Shin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067035/ https://www.ncbi.nlm.nih.gov/pubmed/36420712 http://dx.doi.org/10.1002/cam4.5462

Ejemplares similares

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer
por: Das, Millie, et al.
Publicado: (2023)

Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
por: Lee, Jay M., et al.
Publicado: (2023)

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
por: Criss, Steven D., et al.
Publicado: (2019)

Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer
por: Lin, Julie, et al.
Publicado: (2021)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Methods for Estimating Avoidable Costs of Excessive Alcohol Consumption
por: Gavurova, Beata, et al.
Publicado: (2021)

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2015)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
por: Phua, Lee Cheng, et al.
Publicado: (2020)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States
por: Segal, Barbara, et al.
Publicado: (2009)

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
por: Galsky, Matthew D., et al.
Publicado: (2018)

Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States
por: Smith, Andrew F, et al.
Publicado: (2009)

Assessment of Costs of Avoidable Delays in Intensive Care Unit Discharge
por: Bagshaw, Sean M., et al.
Publicado: (2020)

Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
por: Ogale, S
Publicado: (2018)

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective
por: Jiang, Yunlin, et al.
Publicado: (2023)

Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States
por: Chesson, Harrell W, et al.
Publicado: (2008)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
por: Ogale, Sarika, et al.
Publicado: (2011)

On Measurement of Avoidable and Unavoidable Cost of Alcohol: An Application of Method for Estimating Costs Due To Prior Consumption
por: Jarl, Johan, et al.
Publicado: (2010)

Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature
por: Laserna, Andrés, et al.
Publicado: (2018)

Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model
por: Salcher, Maximilian, et al.
Publicado: (2017)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
por: Li, Ling-Yu, et al.
Publicado: (2019)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Engel-Nitz, Nicole M., et al.
Publicado: (2015)

Atezolizumab-Induced Bell’s Palsy in a Patient With Small Cell Lung Cancer
por: Kichloo, Asim, et al.
Publicado: (2020)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
por: Yamakawa, Hideaki, et al.
Publicado: (2019)

Estimated cost of comprehensive syringe service program in the United States
por: Teshale, Eyasu H., et al.
Publicado: (2019)

Estimating the Cost of Illness of Giant Cell Arteritis in the United States
por: Babigumira, Joseph B., et al.
Publicado: (2017)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis
por: Jansen, Jeroen P, et al.
Publicado: (2014)

A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
por: García-Sánchez, Sebastián, et al.
Publicado: (2022)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
por: Isla, Dolores, et al.
Publicado: (2023)

A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER”
por: Ogale, Sarika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3mhsef9b6l565dqgvcchd4tave